Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotechnology company ViroPharma
So what: The ruling today is important because it allows ViroPharma to adequately ramp up Cinryze production, with the relabeling process of previously produced vials only expected to take six weeks.
Now what: Today's FDA ruling is also important because ViroPharma has been in a world of hurt since the FDA ruled against it in allowing generic competition to enter the market to compete against its previous blockbuster, Vancocin. Since that ruling, both Akorn
Craving more input? Start by adding ViroPharma to your free and personalized Watchlist so you can keep up on the latest news with the company.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.